Sumitomo Pharma Co., Ltd.
DNPUF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $283,571 | $156,640 | $336,429 | $493,952 |
| - Cash | $23,116 | $29,047 | $143,478 | $202,984 |
| + Debt | $305,422 | $427,864 | $334,716 | $269,048 |
| Enterprise Value | $565,877 | $555,457 | $527,667 | $560,016 |
| Revenue | $398,832 | $314,558 | $555,544 | $560,035 |
| % Growth | 26.8% | -43.4% | -0.8% | – |
| Gross Profit | $245,395 | $187,981 | $376,625 | $402,908 |
| % Margin | 61.5% | 59.8% | 67.8% | 71.9% |
| EBITDA | $38,585 | -$317,371 | -$3,498 | $98,315 |
| % Margin | 9.7% | -100.9% | -0.6% | 17.6% |
| Net Income | $23,634 | -$314,969 | -$74,512 | $56,413 |
| % Margin | 5.9% | -100.1% | -13.4% | 10.1% |
| EPS Diluted | 59.49 | -792.79 | -187.55 | 141.99 |
| % Growth | 107.5% | -322.7% | -232.1% | – |
| Operating Cash Flow | $16,500 | -$241,893 | $11,937 | $31,239 |
| Capital Expenditures | -$13,030 | -$15,730 | -$12,742 | -$13,494 |
| Free Cash Flow | $3,470 | -$257,623 | -$805 | $17,745 |